Flash Finance

Mankind Pharma LimitedMANKINDCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹2,275.50
MCap ₹93,988 Cr · P/E 43.1
Mankind Pharma Limited — Stock analysis & AI research Mankind Pharma Limited — Seasonality — best & worst months Mankind Pharma Limited — Technical indicators & charts Mankind Pharma Limited — Technical setup — score, trend, support & resistance Mankind Pharma Limited — Triple Top pattern forming Mankind Pharma Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Promoter Holding Stocks📋 Mid Cap Stocks List 📈 SuperTrend Bearish Signal 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2,964 Cr
Sales · Jun 2026
+16.6% YoY
₹929 Cr
Operating Profit · Jun 2026
+38.0% YoY
31.3%
OPM % · Jun 2026
+18.1% YoY
₹558 Cr
Net Profit · Jun 2026
+35.3% YoY
₹13.53
EPS · Jun 2026
+35.3% YoY

📝 Mankind Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Mankind Pharma Limited reported revenue of ₹2,964 crore for the quarter ended June 2026 (Q1 FY27), up 16.6% from ₹2,541 crore in the same quarter last year, and up 14.8% sequentially over the March 2026 quarter.

Net profit rose 35.3% year-on-year to ₹558 crore, from ₹413 crore. Earnings per share (EPS) came in at ₹13.53.

Operating profit stood at ₹929 crore — an operating margin (OPM) of 31.3%, compared with 26.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Mankind Pharma Limited posted revenue of ₹10,365 crore, a growth of 9.6% over FY25, with a net profit of ₹2,035 crore (up 4.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹10,788 crore with a net profit of ₹2,181 crore.

Valuation snapshot

At the current price of ₹2,275.50, MANKIND has a market capitalisation of ₹93,988 crore and a trailing P/E of about 43.1.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 10th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 72.62%, foreign institutional investors (FIIs) 9.37%, domestic institutional investors (DIIs) 15.56%, public shareholders 2.45% of Mankind Pharma Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹93,988 Cr
Current Price ?
₹2,275.5
P/E ?
43.10above ind
Industry P/E ?
35.00
P/B ?
5.73
P/S ?
8.71
P/FCF ?
40.56
Enterprise Value ?
₹99,559 Cr
EV/EBITDA ?
30.00
PEG ?
2.15
Earnings Yield ?
2.9%
Dividend Yield ?
0.04%
Profitability & Returns
Sales (TTM) ?
₹10,788 Cr
OPM ?
30.8%
Profit after tax (TTM) ?
₹2,181 Cr
EPS (TTM) ?
₹52.80
ROCE ?
14.0%
ROE ?
13.3%
ROA ?
8.9%
Growth
Sales — latest qtr ?
₹2,964 Cr
PAT — latest qtr ?
₹558 Cr
YoY qtr sales growth ?
16.6%
YoY qtr profit growth ?
35.3%
Sales growth (3y) ?
9%
Sales growth (5y) ?
14%
Profit growth (3y) ?
20%
Profit growth (5y) ?
15%
Financial Health
Debt ?
₹5,571 Cr
Debt to Equity ?
0.34
Interest Coverage ?
4.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
72.62%
Change in promoter holding ?
-0.05%
Pledged percentage ?
N/A
Market
Return 3 months ?
-8.4%
Return 6 months ?
7.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,8722,3002,4532,3592,1532,4032,5302,3972,1272,5412,6092,6332,5822,964 +16.6% +14.8%
Operating Profit 381539635603547572752741477673693778919929 +38.0% +1.0%
Other Income 4257586784951067021964785710434 -47.1% -67.3%
Interest 124446219916214714713812595 -35.3% -24.0%
Depreciation 67697790828385871059799108109111 +14.5% +1.9%
Profit Before Tax 355526612576545618770524429494525505788757 +53.3% -4.0%
Net Profit 281409473487454513634416382413459449714558 +35.3% -21.8%
EPS 7.0110.2211.8012.1611.3412.8215.8310.359.2710.0011.1210.8917.2913.53 +35.3% -21.7%
OPM % 20.4% 23.5% 25.9% 25.6% 25.4% 23.8% 29.7% 30.9% 22.4% 26.5% 26.6% 29.6% 35.6% 31.3% +18.1% -12.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹9,456 Cr ₹10,365 Cr ₹10,788 Cr +9.6%
Operating Profit ₹2,542 Cr ₹3,064 Cr ₹3,319 Cr +20.5%
OPM % 26.88% 29.56% 30.77% +10.0%
NPM % 20.59% 19.63% 20.22% -4.7%
Other Income ₹490 Cr ₹302 Cr ₹272 Cr -38.2%
Depreciation ₹361 Cr ₹413 Cr ₹427 Cr +14.3%
Interest ₹370 Cr ₹557 Cr ₹506 Cr +50.7%
EBIT ₹2,181 Cr ₹2,651 Cr ₹2,892 Cr +21.5%
PBT ₹2,341 Cr ₹2,312 Cr ₹2,574 Cr -1.3%
Tax ₹426 Cr ₹202 Cr ₹320 Cr -52.5%
Net Profit ₹1,947 Cr ₹2,035 Cr ₹2,181 Cr +4.5%
EPS ₹48.27 ₹49.30 ₹52.83 +2.1%
Material Cost ₹2,601 Cr ₹1,956 Cr ₹2,135 Cr -24.8%
Employee Cost ₹2,106 Cr ₹1,802 Cr ₹1,901 Cr -14.4%
Extraordinary Items — ₹83 Cr ₹83 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 40404141 +0.0%
Reserves 7,7449,66314,59916,356 +12.0%
Borrowings 5247,2545,571 -23.2%
Other Liabilities 1,5831,7901,9342,658 +37.4%
Total Liabilities 9,37111,51623,82824,625 +3.3%
Fixed Assets 3,1423,5523,4713,959 +14.1%
CWIP 495209207387 +87.0%
Investments 3,1024,21516,68316,523 -1.0%
Other Assets 2,6323,5403,4673,756 +8.3%
Total Assets 9,37111,51623,82824,625 +3.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1,7991,7362,3222,752 +18.5%
Cash from Investing Activity -1,041-1,665-12,179-388 +96.8%
Cash from Financing Activity -710-59,845-2,477 -125.2%
Net Cash Flow 4866-11-113 -927.3%
Free Cash Flow 1,2191,4561,9692,317 +17.7%
CFO/OP 123%95%109%105% -3.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 22333441 +20.6%
Inventory Days 132160153151 -1.3%
Days Payable 103757995 +20.3%
Cash Conversion Cycle 5211810897 -10.2%
Working Capital Days 4055-48-51 -6.2%
ROCE % 21%24%15%14% -6.7%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 72.67%72.67%72.66%72.66%72.63%72.62% -0.0%
FIIs 13.07%12.83%11.34%10.24%9.45%9.37% -0.8%
DIIs 11.50%11.91%13.26%14.46%15.39%15.56% +1.1%
Public 2.75%2.57%2.75%2.63%2.53%2.45% -3.2%
No. of Shareholders 1,79,5491,70,3471,77,5391,77,6061,66,7151,63,770 -1.8%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Mankind Pharma Limited's revenue in Q1 FY27?
Mankind Pharma Limited reported revenue of ₹2,964 crore for the quarter ended June 2026 (Q1 FY27), up 16.6% from ₹2,541 crore in the same quarter last year, and up 14.8% sequentially over the March 2026 quarter.
What was Mankind Pharma Limited's net profit in Q1 FY27?
Net profit rose 35.3% year-on-year to ₹558 crore, from ₹413 crore. Earnings per share (EPS) came in at ₹13.53.
What is MANKIND's market capitalisation and P/E ratio?
At the current price of ₹2,275.50, MANKIND has a market capitalisation of ₹93,988 crore and a trailing P/E of about 43.1.
Who owns Mankind Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 72.62%, foreign institutional investors (FIIs) 9.37%, domestic institutional investors (DIIs) 15.56%, public shareholders 2.45% of Mankind Pharma Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI